VIA
DSGN icon

Virtus Investment Advisers’s Design Therapeutics DSGN Stock Holding History

Virtus Investment Advisers’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$432K Buy
+29,827
New +$372K 0.1% 240
2023
Q1 		– Sell
-14,400
Closed -$148K – 295
2022
Q4 		$148K Hold
14,400
– – 0.1% 231
2022
Q3 		$241K Buy
+14,400
New +$287K 0.11% 174

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Virtus Investment Advisers's DSGN Position: Q2 2026 in Review

Virtus Investment Advisers opened a new position in Design Therapeutics (DSGN) in Q2 2026: 29,827 shares worth $432K. The stake represents 0.1% of the portfolio and ranks #240 among its holdings. This is a return to the name: Virtus Investment Advisers previously reported a position in DSGN as recently as Q4 2022.

Virtus Investment Advisers first reported a position in DSGN in Q3 2022 and has held it in 3 quarters since. 136 funds tracked by Wall St. Rank hold DSGN as of Q2 2026.

  • Virtus Investment Advisers held 29,827 shares of Design Therapeutics worth $432K as of Q2 2026.
  • Design Therapeutics was a new Virtus Investment Advisers position in Q2 2026.
  • Design Therapeutics made up 0.1% of Virtus Investment Advisers's portfolio in Q2 2026, its #240 holding.
  • Virtus Investment Advisers first reported a position in Design Therapeutics in Q3 2022 and has held it in 3 quarters since.
  • 136 funds tracked by Wall St. Rank held Design Therapeutics as of Q2 2026.

Based on Virtus Investment Advisers's 13F filing for Q2 2026, filed 11 Aug 2026.